RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its fourth
quarter and full year 2010 financial results will be released on
Thursday, February 10, 2011. BioCryst will host a conference call and
Web cast at 11:00 a.m. Eastern Time to discuss the financial results and
to provide an update on the Company's programs. The call will be led by
Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant,
Chief Financial Officer and Dr. William P. Sheridan, Chief Medical
Officer.
The Web cast can be accessed by logging onto www.biocryst.com.
Please connect to the Web site at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be needed. To participate in the conference call, please dial
1-877-303-8027 (United States) or 1-760-536-5165 (International). No
passcode is needed for the call. The audio portion of the Web cast will
be archived and available for replay for at least 14 days.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development:
peramivir, a neuraminidase inhibitor for the treatment of influenza,
BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the
treatment of gout, and forodesine, an orally-available PNP inhibitor for
hematological malignancies. Utilizing crystallography and
structure-based drug design, BioCryst continues to discover additional
compounds and to progress others through pre-clinical and early
development to address the unmet medical needs of patients and
physicians. For more information, please visit the Company's Web site at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910 (investors)
Source: BioCryst Pharmaceuticals
News Provided by Acquire Media